Abstract
Background: Glaucoma is a chronic, vision-threatening disease, and a major cause of legal blindness. The current view is no longer limited to the progressive optic nerve injury, since growing evidence strongly support the interpretation of glaucoma as a complex neurodegenerative disease. However, the precise pathogenic mechanisms leading to the onset and progression of central nervous system (CNS) impairment, and the functional consequences of this damage, are still partially understood. The main aim of this review is to provide a complete and updated overview of the current knowledge regarding the CNS involvement in glaucoma, and the possible therapeutic perspectives.
Methods: We made a careful survey of the current literature reporting all the relevant findings related to the cognitive dysfunctions occurring in glaucoma, with specific remarks dedicated on the higher-order visual function impairment and the possible employment of neuroprotective agents.
Results: The current literature strongly support the interpretation of glaucoma as a multifaceted chronic neurodegenerative disease, widely affecting the CNS. The cognitive impairment may vary in terms of higher-order functions involvement and in the severity of the degeneration. Although several neuroprotective agents are currently available, the development of new molecules represents a major topic of investigation for future clinical trials.
Conclusions: Glaucoma earned the right to be fully considered a neurodegenerative disease. Glaucomatous patients may experience a heterogeneous set of visual and cognitive symptoms, progressively deteriorating the quality of life. Neuroprotection is nowadays a necessary therapeutic goal and a future promising way to preserve visual and cognitive functions, thus improving patients’ quality of life.
Introduction
The term “glaucoma” refers to a group of optic neuropathies characterized by degeneration of retinal ganglion cells (RGCs) and their axons. Their damage lead to the progressive thinning of retinal nerve fibers layer (RNFL) and cupping of the optic nerve head (ONH). Structural changes result in characteristic visual field (VF) alterations, up to complete blindness. Glaucoma is considered a leading cause of blindness worldwide and it is estimated that the number of affected people will increase to approximately 111.82 million in 2040 (Pascolini and Mariotti, 2012; Tham et al., 2014). The main cause of this is that life expectancy is growing, and age is one of the major risk factors for glaucoma (Pascolini and Mariotti, 2012; Tham et al., 2014). The prevalence of primary open-angle glaucoma (POAG), the most common form of glaucoma in the Caucasians, increases significantly with age and many patients develop POAG around 60 years old, reaching a remarkably high incidence (at least 7%) in the Barbadian population (Wensor et al., 1998; Gordon et al., 2002; Leske et al., 2004; European Glaucoma Prevention Study (EGPS) Group, 2007). Ocular hypertension (OHT) is an important risk factor in the development of glaucoma and in its progression (The AGIS Investigators, 2000; Gordon et al., 2002; Heijl et al., 2002). According to the mechanical theory of glaucoma, OHT is the result of a backward displacement of the lamina cribrosa, which in turn would damage the axons of RGCs, compressing them between its meshes. Whereas increased IOP is likely to explain the pathogenesis of optic nerve damage in certain types of glaucoma, this may not be true for some other forms. In particular, normal tension glaucoma (NTG), which afflicts approximately 15–25% of glaucomatous patients, is a clinical condition in which, despite pathologic cupping of the ONH and characteristic VF alterations, IOP is within the normal range (Collaborative Normal-Tension Glaucoma Study Group, 1998; Kim and Park, 2016; Mallick et al., 2016). A relevant proportion of patients is characterized by different patterns of progression; the estimated prevalence of fast-progressors is between 4–10%, and this subtype of patients is characterized by high risk of visual disability (Chauhan et al., 2014; Kirwan et al., 2014; Jammal et al., 2021). To explain NTG-related damages, various non-IOP dependent pathogenetic mechanisms have been proposed, like chronic hypoxia and ischemia, increased intracranial pressure, neuronal glutamate-induced excitotoxicity, mitochondrial dysfunction, oxidative stress, and autoimmunity (Hayreh, 1985; Flammer, 1994; Morgan et al., 1995, 1998, 2002; Romano et al., 1995, 1999; Dreyer et al., 1996; Tezel et al., 1998, 1999; Osborne et al., 2001; Flammer et al., 2002; Gherghel et al., 2005; Grieshaber and Flammer, 2005; Abu-Amero et al., 2006; Grus et al., 2006; Salt and Cordeiro, 2006; Ju et al., 2007; Berdahl et al., 2008a, b; Ren et al., 2010, 2011; Jonas, 2011; Chrysostomou et al., 2013; Siaudvytyte et al., 2014, 2015). Taking together all these factors, a more comprehensive view of glaucoma should be considered, assuming neurodegeneration as a key component of glaucoma pathogenesis. Indeed, many of the above-mentioned mechanisms have been proposed to explain the pathogenesis of neurodegenerative diseases of the central nervous system (CNS). Chronic hypoxia and ischemia account for the development of vascular dementia, which is the second most common cause of irreversible cognitive dysfunction after Alzheimer disease (AD). Excitotoxicity phenomena have been implicated in post-stroke cellular damage and in certain neurodegenerative diseases such as Huntington’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and AD (Szatkowski and Attwell, 1994; Rego and Oliveira, 2003). In addition, glaucoma shares some characteristics with neurodegenerative diseases: increased incidence with age, insidious onset, progressive deterioration, and, frequently, a recognized genetic predisposition. This latter is characterized by the involvement of several genes, including myocilin, cytochrome P450 B1 and optineurin (Park et al., 2007; Kumar et al., 2016, 2017). In this complex scenario, this review would explore the clinical similarities between neurodegenerative disorders and glaucoma, the features that seem consistent with neurodegenerative mechanisms characterizing the pathogenesis of glaucoma, and the CNS changes occurring in glaucoma.
Methods
We searched all English language and human subject articles using keywords search of MEDLINE library. The keywords included the following: glaucoma, open angle glaucoma, normotensive glaucoma, OHT, neurodegeneration, neurodegenerative disease, neuroplasticity, neuroretina, optic nerve, ONH, multimodal imaging, neuroimaging. All the references were carefully examined by two expert researchers (AA,EA) which collected and ordered all the relevant information, considering the main topic of this review as expressed in the manuscript title.
Multimodal Imaging of The Eye Applied on Glaucoma
Multimodal imaging radically changed the diagnostic approach to posterior segment diseases. This is intended as a set of non-invasive tools assessing different morphological characteristics of the retina and the ONH. Fundus autofluorescence is able to detect the light absorption and emission properties of retinal fluorophores characterizing normal retina and pathological conditions (Schmitz-Valckenberg et al., 2008). Although representing a very important diagnostic tool in retinal diseases, its usage in glaucoma setting is still limited. However, some studies describing ONH autofluorescence changes occurring in glaucoma and the correlation with retinal fibers thinning suggest the utility of this multimodal imaging technique also in glaucoma setting (Viestenz et al., 2006; Reznicek et al., 2013). Optical coherence tomography (OCT) is a laser-based technique able to investigate reflectivity properties of retinal structures and to provide histology-like information (Thomas and Duguid, 2004). It’s role in glaucoma setting is fundamental since it allowed to quantitatively detect ganglion cells layer (GCL) and RNFL alterations and to progressively monitor their evolution with very high accuracy (Leung et al., 2010; Langenegger et al., 2011; Tong et al., 2021). It represents an extremely sensitive, reliable, and reproducible diagnostic approach, and nowadays is of very high utility in the diagnosis and management of glaucoma (Figure 1; Leung et al., 2010; Tong et al., 2021). A recent evolution of OCT is represented by OCT angiography (OCTA), which is able to detect motion signal coming from erythrocytes and to reconstruct intraretinal capillaries (Spaide et al., 2018). If OCTA is of great utility in other retinal diseases, its role in glaucoma setting is still limited. Several previous papers tried to detect early vascular biomarkers of glaucoma onset and progression, demonstrating significant correlations between alterations of the deep capillary plexus and the radial peripapillary capillaries with structural OCT changes and VF damages, thus reinforcing the role of OCTA employment in glaucoma diagnostic workup (Lee et al., 2016; Spaide et al., 2018; Van Melkebeke et al., 2018; Bojikian et al., 2019; Li et al., 2021). A recent report of the American Academy of Ophthalmology highlighted how the quantitative evaluation of vessel density alterations through OCTA may complement the other diagnostic modalities in glaucoma setting (Figure 1; WuDunn et al., 2021).
Figure 1
Ophthalmic Manifestations of Neurodegenerative Diseases
The eye is often defined as a “window into the brain,” for the big amount of neuroanatomical and vascular information achievable by means of non-invasive diagnostic modalities. Several ocular and visual manifestations have been previously described as complained by patients affected by mild cognitive impairment (MCI) and AD, including extraocular muscles impairment, pupillary defects, RNFL and GCL thinning and visual alterations (for example contrast sensitivity, color vision, VF, visuomotor coordination; Hinton et al., 1986; Trick et al., 1995; Lakshminarayanan et al., 1996; Rizzo et al., 2000; Gilmore et al., 2006; Scinto, 2007; Garbutt et al., 2008; Kavcic et al., 2011; Lee and Pai, 2012; Risacher et al., 2013; Coppola et al., 2015; Liu et al., 2015). In this context, the eye is not a passive viewer of the neurodegenerative cascade occurring in the CNS but is directly involved in MCI/AD pathogenesis. Several studies reported wide accumulations of amyloid-beta precursor protein and β-amyloid within the inner retinal layers (Ning et al., 2008; Koronyo et al., 2012). Furthermore, OCTA was able to detect statistically significant alterations of the intraretinal vascular network in AD patients (van de Kreeke et al., 2020; Wang et al., 2021). The level of evidence regarding the role of retinal diagnostic tools for the early detection of AD is growing, thus promoting the eye as an early biomarker of neurodegenerative disorders (Lim et al., 2016; Cerquera-Jaramillo et al., 2018; Colligris et al., 2018). Similar considerations may be done also considering other neurodegenerative diseases, first of all PD. Although it was mainly considered as a motor disorder, the current point of view regarding PD is changing, nowadays considering this as a complex neurodegenerative disease (Armstrong, 2008). Visual manifestations in PD include a widespread set of alterations involving almost all eye and visual system components (Armstrong, 2011). Interestingly, morpho-functional changes and visual dysfunctions may occur also many years before the onset of motor disorders, both involving the eye and the intracranial visual system, thus strongly suggesting the adoption of ocular findings as early biomarkers of PD onset (Armstrong, 2011; Arrigo et al., 2017a, b, 2018; Guo et al., 2018; Cuerca, 2019; Sung et al., 2019). All these findings provide the basis to explain the wide range of visual alterations complained by patients affected by neurodegenerative diseases. In Table 1 the main visual dysfunction described in two of the most important and representative neurodegenerative diseases, namely AD and PD, are shown. If in this section we described the eye as a structure damaged by pathogenic sources having their primary site in the brain, it should be considered that primary degeneration of ocular structures may induce remarkable changes of the CNS, thus placing the basis for assessing that the neurodegeneration in the eye may somehow have an impact on the neurodegeneration in the brain. The CNS changes occurring as the consequence of primary eye disorders are discussed in the next sections.
Table 1
| Alzheimer Disease | Parkinson Disease |
|---|---|
| Visual acuity reduction | Visual acuity reduction |
| Visual field alterations | Visual field alterations |
| Color discrimination impairment | Color discrimination impairment |
| Electrophysiology alterations | Eye movements function deficits |
| Contrast and temporal discrimination impairment | Pupil function and reactivity decreases |
| Visual and visuo-motor tasks alterations | Electrophysiology alterations |
| Visual hallucinations | Contrast and temporal discrimination impairment |
| Posterior pole morpho-functional alterations | Visual and visuo-motor tasks alterations |
| Balint’s syndrome (simultanagnosia + ocular motor apraxia + optic ataxia) | Visual hallucinations |
| Corneal nerves alterations | Corneal nerves alterations |
| Retinal and optic nerve morpho-functional alterations | Retinal and optic nerve morpho-functional alterations |
| Intracranial visual system morpho-functional changes | Intracranial visual system morpho-functional changes |
Main visual system alterations in neurodegenerative diseases.
Neurodegenerative Manifestations in Ophthalmic Diseases
The other side of the coin is the involvement of the CNS in ophthalmic diseases, representing a topic of growing interest for the clinical and scientific communities (Prins et al., 2016). Indeed, posterior segment disorders can induce neurodegenerative and neuroplasticity phenomena within the brain, towards anterograde and retrograde transsynaptic mechanisms. Age-related macular degeneration is associated with deep degenerative changes of the intracranial visual pathways, functional impairment of visual and visuomotor tasks and CNS connectivity network modifications induced by neuroplasticity phenomena (Lešták et al., 2013; Rosengarth et al., 2013; Hernowo et al., 2014). Similar changes may occur also in inherited retinal dystrophies, where white matter network changes and cortical remapping have been described (Olivo et al., 2015; Ferreira et al., 2016; Rita Machado et al., 2017). If visual system changes occur in the first stages to try to compensate the progressive visual degeneration, the later stages of retinal diseases are characterized by extensive morpho-functional impairment also of the intracranial visual system (Nuzzi et al., 2020). Although still poorly investigated, the profound interconnection between the eye and CNS may have extremely important implications for a deeper understanding of visual processing mechanisms and for ocular and CNS diseases.
Glaucoma as A Neurodegenerative Disease
The eye and the brain are strictly interconnected through the optic nerve and even growing evidence support the existence of a strong morpho-functional interconnection between these two compartments, allowing to share common pathogenic neurodegenerative pathways and manifestations. The most used models to assess the similarities between eye and brain neurodegeneration are glaucoma and AD. First of all, these two diseases are characterized by the similar retinal sites of damage, namely GCL and RNFL (Blanks et al., 1996a, b). Ganglion cells loss is mainly caused by increased oxidative and metabolic distress, neuroinflammation-mediated damage, and increased glial cells reactivity (McKinnon, 2012; Sivak, 2013; Jindal, 2015; Wei et al., 2019; Volkert and Crowley, 2020).
In this intricated scenario, glaucoma can be fully considered as a complex neurodegenerative disease. Indeed, the pathogenic features characterizing the progressive morpho-functional disruption of the neuroretinal structures and the patterns of involvement of the CNS in glaucoma share many common characteristics with other neurodegenerative disorders. A key molecular mechanism occurring in glaucoma is the neuroinflammation, a complex cascade of multifactorial events leading to the damage of neuroretinal structures (McKinnon, 2012; Wei et al., 2019; Jiang et al., 2020; Quaranta et al., 2021). Likely AD, glaucomatous damage is promoted by the activation of tumor necrosis factor-alpha and complement system pathways (Stasi et al., 2006; Tezel, 2008). Several autoantibodies of neuroinflammation and neurodegeneration have been found highly present in glaucomatous patients, with different patterns of expression between POAG and NTG (Vu et al., 2019). In addition, other circulating biomarkers associated with neurotrophy, neuroprotection and oxidative stress have been found altered in glaucoma, including serum homocysteine, vitamin B12, folic acid and endothelin-1 (ET-1; Cumurcu et al., 2006; Turgut et al., 2010; Türkcü et al., 2013; López-Riquelme et al., 2015). Another remarkable similarity between glaucoma and AD is represented by the presence of amyloid precursor protein accumulations in glaucomatous eyes (McKinnon et al., 2002).
Amyloid-β protein and its precursor are a major pathogenic source of damage, turning out to be at the center of several pathogenic cascades leading to the activation and promotion of neurodegeneration. The role of amyloid-β in the retina is still unknown, although previous authors hypothesized an antimicrobial activity, similarly to what found within the CNS (Wostyn et al., 2015; Kumar et al., 2016; Naaman et al., 2020). On the other side, amyloid precursor protein is known to exert several neuroprotective activities, including the support to synaptogenesis and the promotion of neuronal development and survival (Jessen et al., 2015). This is true when amyloid-β and amyloid precursor protein maintain monomeric configuration. However, it has been described the spontaneous aggregation of amyloid-β into dimers, trimers, and oligomers; the insoluble form of amyloid-β oligomers lead to the formation of protofibrils, fibrils, and insoluble amyloid plaques which are toxic for retinal neurons, activating several pathologic cascades similarly to what happen within the brain in AD (Naaman et al., 2020). Furthermore, amyloid precursor protein physiologically interacts with other molecules, including integrins and receptor tyrosine kinase; the impairment of this metabolic network was associated with tau-related excitotoxicity causing synaptic and axonal failure.
In glaucoma, a possible pathogenic hypothesis of amyloid-β accumulation has been based on the dysfunction of the retinal glymphatic system (Wostyn et al., 2015). Indeed, the retina as well as the brain have no lymphatic vessels; for this reason, glial cells may work as scavenger elements, towards the aquaporins system, to allow the drainage of fluids and molecules (Jessen et al., 2015). The glymphatic system involvement in glaucoma might be based on the impaired outflow and stasis caused by changes of the pressure barrier across the lamina cribrosa. This latter is the result of a delicate balance of the intraocular and the intracranial pressures; an increased IOP or a decreased intracranial pressure may be the cause of the glymphatic system disruption (Wostyn et al., 2016; Wang et al., 2020; Wang and Mao, 2021).
Several evidences described other interesting molecular mechanisms significantly associated with the onset and progression of glaucomatous damage, including the disbalance of neurotrophic factors production, the reactive activation of glial cells, increased oxidative stress, dysregulation of the immune system, and energetic demand caused by mitochondrial dysfunction (Tezel and Wax, 2000; Tezel, 2006, 2021; Ju et al., 2009; Baudouin et al., 2021). In this context, increasing IOP values may act as a trigger for the onset of these pathogenic mechanisms, although these may independently occur, like in NTG (Munemasa and Kitaoka, 2013). Even growing studies are defining a multifactorial pathogenic scenario leading to the onset and progression of NTG, where several mechanisms including vascular dysregulation, mainly caused by ET-1-dependent endothelial dysfunction (Moore et al., 2008), glial cells reactivity, leading to neuroinflammatory and oxidative distresses (Tezel and Wax, 2004; Mozaffarieh and Flammer, 2013), impairment of exchanges towards the lamina cribrosa (Tezel and Wax, 2004; Rao et al., 2007, 2008), and blood-brain barrier disruption (Hofman et al., 2001; Grieshaber and Flammer, 2007). Other demonstrated neurotrophic deprivations regarded the reduced production and release of neurotrophins and brain-derived neurotrophic factor (Vrabec and Levin, 2007). These molecules are mainly released by Muller cells and are fundamental for neuronal cell survival (Vrabec and Levin, 2007). The involvement of Muller cells and other glial cytotypes resulted extremely important in the pathogenesis of glaucoma, leading to the progressive loss of retinal and optic nerve homeostasis, promoting neuroinflammation and neurodegeneration processes (Seki et al., 2005; Vrabec and Levin, 2007; Seitz et al., 2013; Chong and Martin, 2015). It is worth of notice that all these mechanisms are far from the pathogenic cascade which can be induced by the mere IOP value increases. All the main mechanisms characterizing neurodegeneration in glaucoma are shown in Figure 2. In addition to all these factors making the neurodegenerative pathogenesis of glaucoma extremely complex, growing findings add a further cause of damage, represented by the impairment of the homeostatic brain and eye fluid balance. Indeed, decreased ocular and brain blood flows, cerebrospinal fluid disbalances, higher vascular resistance and diffuse cerebral hypoperfusion/ischemic changes have been described in glaucoma patients (Harris et al., 2003; Heringa et al., 2013). This chronic sufferance is not limited to the retina and the ONH.
Figure 2
Indeed, what is of great interest is the number of changes and damages occurring at the level of the CNS. Magnetic resonance imaging (MRI) techniques described widespread modifications of the white matter tissue and the brain connectivity in patients affected by glaucoma, with strong correlations with RNFL/GCL impairment and VF alterations (Garaci et al., 2009; El-Rafei et al., 2013; Omodaka et al., 2014; Zhao et al., 2021). Similarly, several gray matter thinning of the visual cortex have been also described (Zhang et al., 2015; Zhou et al., 2017; Giorgio et al., 2018). Gray matter thinning involved also other brain regions over than the occipital cortex, including lingual gyrus, calcarine gyrus, postcentral gyrus, superior frontal gyrus, inferior frontal gyrus, rolandic operculum, cerebellar cortex, and hippocampus (Li et al., 2012, 2020; Frezzotti et al., 2014). On the other side, some other gray matter regions associated with visual processing turned out to be thicker in patients with glaucoma, including middle temporal gyrus, inferior parietal gyrus, angular gyrus, midbrain, brainstem, frontal gyrus, cerebellar vermis and thalamus (Jiang et al., 2017; Giorgio et al., 2018; Kasi et al., 2019). The wide involvement of extra-occipital regions may justify previous findings reporting significant alterations of white matter connections involved in visual and visuomotor tasks, and in high order functions, including the inferior fronto-occipital fasciculus, the longitudinal and the inferior frontal fasciculi, putamen, caudate nucleus, anterior and posterior thalamic radiations and anterior and posterior limbs of the internal capsule (Zikou et al., 2012; Williams et al., 2013). Although the whole CNS alterations significantly correlated with the stage of glaucoma and disease’s severity (Wang et al., 2021), many studies highlighted how gray and white matter extensive changes may be detected already at early stages of glaucomatous disease (Yu et al., 2013; Frezzotti et al., 2016; Kasi et al., 2019) thus supporting the hypothesis that the CNS involvement is not only a secondary phenomenon related with optic nerve damage, but it may represent the result of an active cascade of pathological mechanisms evolving independently from the optic nerve degeneration. Taking together all the above described visual and non-visual brain connectivity alterations, it may be assumed that glaucomatous patients may suffer from brain processing dysfunctions localized at different levels, including visual and visuomotor tasks, memory and emotion, working memory and attention, default mode network and other multimodal brain functions (Zhang et al., 2016; Wang et al., 2017; Nuzzi et al., 2018; Giorgio et al., 2020).
Cognitive Impairment in Glaucoma
Cognitive impairment is a relatively novel concept described in glaucoma, which is gaining increased attention and importance. It represents a progressive decline of memory and multimodal high order brain functions, which is usually categorized, accordingly with the gravity of the cognitive deterioration, as MCI or dementia (Petersen, 2011; Jongsiriyanyong and Limpawattana, 2018). An increasing body of literature reported high frequency of cognitive impairment in patients affected by glaucoma than in normal controls (Harrabi et al., 2015; Su et al., 2016; Maurano et al., 2018; Varin et al., 2020). On the other side, patients with AD and dementia had an increased risk of glaucoma onset (Xu et al., 2019; Vidal et al., 2020). The link between these two apparently different conditions is further reinforced by the common finding of RNFL/GCL thinning and visual gray and white matters morpho-functional impairments (Iseri et al., 2006; Tamura et al., 2006; Ascaso et al., 2014; Jones-Odeh and Hammond, 2015). The relationship between retinal and CNS alterations is strong and support the role of OCT-based technology for the early diagnosis of cognitive dysfunctions and neurodegenerative diseases (Biscetti et al., 2021). A well-known glaucoma-related finding is the thinning of the lamina cribrosa, a complex tissue surrounding the ONH and providing structural and functional supports to the ganglion cells. Interestingly, lamina cribrosa thinning was found significantly associated with worse global cognitive function [measured by Mini-Mental State Exam (MMSE) score], independently from the severity of glaucoma (Lee et al., 2020). The cognitive impairment in glaucoma, measured by means of different cognitive assessment tests, opens new management issues with respect to the reliability of VF examination; many studies showed a significant relationship between neurocognitive decline and VF variability, placing a solid basis for a remarkable structure-function relationship mismatch which may interfere with the proper management of glaucomatous patients (Diniz-Filho et al., 2017; Honjo et al., 2017; Raman et al., 2019). Indeed, decreased VF test reliability can delay the detection of true progression of the disease, potentially resulting in irreversible visual function loss. Conversely, false VF worsening, when no true changes occur, may lead to unnecessary treatment changes with potential negative effects for patients. On the other hand, visual function decrease may contribute to cognitive deterioration, because of leading patients to lower daily activity levels and progressive loss of self-sufficiency, especially in older ages (Bassuk et al., 1999; Wilson et al., 2002). As above described, the involvement of the CNS and the impairment of cognitive functions in glaucoma is ruled by extensive changes of functional connectivity networks, with increased phenomena of neuroplasticity and neurodegeneration. Because of its relatively recent discovery, few studies have been conducted focusing on cognitive dysfunctions in glaucoma. However, if considering the importance of the visual function in cognitive tasks, this research field should be object of further investigations in glaucoma. Just to provide an example, it was demonstrated that sensory functions impairments have a direct role in cognitive aging, since good sensory functions, with particular regard to visual task, were found strongly predictive of the cognitive performance (Glass, 2007). Interestingly, each visual function has a different impact on cognitive impairment, with contrast sensitivity seeming to have the strongest relationship with cognitive tests scores (Varadaraj et al., 2021). It is worth of notice that glaucomatous patients are characterized by significantly higher impairment of contrast sensitivity, with respect to normal aging (McKendrick et al., 2007). On this basis, it is assumable that glaucoma could alter cognitive performance, especially in advanced stages (McCoskey et al., 2018; Mullany et al., 2021). This is the reason why future research should be focused on the deep assessment of the pathologic cascades occurring beyond the eye, in order to draw more definite conclusion about the impact of glaucomatous changes on brain high order functions.
Based on what described in this review, the careful assessment of CNS involvement might pave the stone for future diagnostic and therapeutic challenges, guiding clinicians and researchers on a more comprehensive evaluation of the pathophysiology of glaucoma and improvements in the management of visual and non-visual alterations complained by glaucomatous patients.
Future Perspectives
The current management of glaucoma is mainly based on IOP-lowering medications and IOP-lowering surgical approaches. Although IOP control is a crucial step for the management of glaucomatous patients, what discussed in the present review opens new perspectives in the fields of diagnostic workup and treatment of glaucoma. The awareness regarding the extensive involvement of the CNS, causing the onset of several non-ocular dysfunctions, offers the basis for the development of new treatment strategies dedicated on neuroprotection. Since glutamate-induced excitotoxicity is a main factor associated with glaucomatous neurodegeneration, a possible therapeutic approach might be based on the employment of glutamate inhibitors, such as dizocilpine maleate, memantine and Bis(7)-tacrine (Lipton, 2003; Guo et al., 2006; Fang et al., 2010). These N-methyl D-aspartate (NMDA) receptor blockers act as potent inhibitors of glutamate, although the level of evidence regarding their positive effect in glaucoma setting is not still high and sometimes these molecules resulted toxic for neurons. Furthermore, the administration of memantine was not associated with statistically significant lowering of glaucoma progression. Another class of molecules currently under investigation is represented by ginkgo biloba extracts. Ginkgo biloba already showed positive effects against cognitive impairment in neurodegenerative diseases, such as AD, and positive findings have been reported in glaucoma, thus suggesting a therapeutic role for glaucomatous patients (Quaranta et al., 2003). Brimonidine is a selective alpha-2 receptor adrenergic agonist binding receptors localized within the retina and increasing retinal metabolism and neuronal growth. The rationale regarding the use of brimonidine in glaucoma is based on the neuroprotective role that this molecule should have for retinal ganglion cells, thus preventing their degeneration (Kalapesi et al., 2005). Other therapeutic perspectives are based on the employment of antioxidants, vasoprotective agents, other anti-neurotoxic molecules, such as nitric oxide synthase inhibitors and calcium-channel blockers, other neurotrophic factors, such as BDNF and ciliary neurotrophic factor, and stem cells approaches (Doozandeh and Yazdani, 2016). The main clinical trials dedicated on neuroprotective therapeutic approaches in glaucoma setting are listed in Table 2. It is worth of notice that two interventional studies are currently active, focused on NT-501 encapsulated cell therapy implant for increasing the production of ciliary neurotrophic factor (NCT02862938) and on testing GlaucoCetin nutraceutical approach (NCT04784234), respectively. With respect to clinical trials focused on cognitive impairment in glaucoma, few studies are currently registered on https://clinicaltrials.gov/. NCT01303939 is a MRI-based clinical trial started in 2011 and ended in 2013 adopting neuroimaging approaches to assess CNS involvement in glaucoma. NCT03333096 is a trial started in 2017, focused on drive fitness and cognitive performance including attention assessments in patients affected by glaucoma and MCI by means of specific neuropsychological tests. NCT03318549 is a clinical trial started in 2017 with the aim of administering visual tasks performance tests to assess visual functional impairment in different eye disorders, including glaucoma.
Table 2
| Clinical trials dedicated on neuroprotection in glaucoma | |||||
|---|---|---|---|---|---|
| Number | Study Title | Identifier | Drug/Approach | Target | Status |
| 1 | A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma | NCT02862938 | NT-501 encapsulated cell therapy implant | Production of ciliary neurotrophic factor | Active, not recruiting |
| 2 | A Prospective Randomized Controlled Trial of GlaucoCetin vs. Placebo in Glaucoma Patients With Visual Field Loss. | NCT04784234 | GlaucoCetin | Neuroprotection | Recruiting |
| 3 | A Multicenter, Double-Masked, 2-Arm Parallel Group Study Comparing the Effect of Brimonidine 0.2% vs. Timolol 0.5% on Visual Field Stability in Patients With Low-Pressure Glaucoma | NCT00317577 | Brimonidine | Neuroprotection | Completed 2004 |
| 4 | Topical Brimonidine vs. Argon Laser Trabeculoplasty in Progressing Human Glaucoma. A Prospective Randomized Clinical Trial. | NCT00466479 | Brimonidine | Neuroprotection | Completed 2007 |
| 5 | A Phase II Study to Investigate the Safety, Efficacy, and Pharmacokinetic Profile of Twice-Daily DNB-001 in Previously Untreated Patients With Elevated Intraocular Hypertension | NCT00683501 | DNB-001 | Ion channel modulator | Completed 2008 |
| 6 | Impact of Oral Versatile Antioxidants on Glaucoma Progression:Comparative Early Results | NCT01544192 | Gingko Biloba; α-tocopherol | Neuroprotection | Completed 2012 |
| 7 | Impact of Oral Versatile Antioxidants on Glaucoma Progression:Comparative Early Results | NCT01544192 | Gingko Biloba; α-tocopherol | Neuroprotection | Completed 2012 |
| 8 | CNTF Cell Implants For Glaucoma: A Phase I Study | NCT01408472 | NT-501 encapsulated cell therapy implant | Production of ciliary neurotrophic factor | Completed 2014 |
Clinical trials dedicated on neuroprotection in glaucoma (from https://clinicaltrials.gov/).
Conclusion
This review tried to collect the main findings supporting the existence of many elements in common between neurocognitive dysfunctions in glaucoma and neurodegenerative diseases, leading to MCI/dementia. The eye and the CNS are closely interconnected, placing the basis for the onset of visual symptoms in neurodegenerative diseases and, conversely, of neurocognitive dysfunctions in ophthalmic disorders. Glaucomatous patients are characterized by a wide range of still poorly investigated cognitive dysfunctions. These alterations, governed by neuroinflammatory and neurodegenerative mechanisms, may have a strong impact on patients’ quality of life and may remarkably interfere with the proper diagnostic and therapeutic management of glaucoma. Although still representing a novel research field, the vision of glaucoma as a complex neurodegenerative disease would open new diagnostic and therapeutic routes, more focused on the involvement of the neuroretinal and the CNS structures. Further studies should be focused on a deeper assessment of CNS alterations in glaucoma and on the development of new neuroprotective therapeutic strategies.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
AA and EA: review design, data analysis, data interpretation, and manuscript draft. AS, DA, and FF: data acquisition and data analysis. MB and FB: data interpretation, manuscript revision, and study supervision. All authors contributed to the article and approved the submitted version.
Conflict of interest
FB consultant for Alcon (Fort Worth, Texas, USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc. (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch and Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), Novagali Pharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), Zeiss (Dublin, California, USA). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Abu-AmeroK. K.MoralesJ.BosleyT. M. (2006). Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci.47, 2533–2541. 10.1167/iovs.05-1639
2
ArmstrongR. A. (2008). Visual signs and symptoms of Parkinson’s disease. Clin. Exp. Optom.91, 129–138. 10.1111/j.1444-0938.2007.00211.x
3
ArmstrongR. A. (2011). Visual symptoms in Parkinson’s disease. Parkinsons Dis.2011:908306. 10.4061/2011/908306
4
ArrigoA.CalamuneriA.MilardiD.MorminaE.RaniaL.PostorinoE.et al. (2017a). Visual system involvement in patients with newly diagnosed Parkinson disease. Radiology285, 885–895. 10.1148/radiol.2017161732
5
ArrigoA.CalamuneriA.MorminaE.AragonaP.GaetaM.QuartaroneA. (2017b). MRI findings of visual system alterations in Parkinson’s disease. Brain140:e69. 10.1093/brain/awx244
6
ArrigoA.RaniaL.CalamuneriA.PostorinoE. I.MorminaE.GaetaM.et al. (2018). Early corneal innervation and trigeminal alterations in Parkinson disease: a pilot study. Cornea37, 448–454. 10.1097/ICO.0000000000001517
7
AscasoF. J.CruzN.ModregoP. J.Lopez-AntonR.SantabárbaraJ.PascualL. F.et al. (2014). Retinal alterations in mild cognitive impairment and Alzheimer’s disease: an optical coherence tomography study. J. Neurol.261, 1522–1530. 10.1007/s00415-014-7374-z
8
BassukS. S.GlassT. A.BerkmanL. F. (1999). Social disengagement and incident cognitive decline in community-dwelling elderly persons. Ann. Intern. Med.131, 165–173. 10.7326/0003-4819-131-3-199908030-00002
9
BaudouinC.KolkoM.Melik-ParsadaniantzS.MessmerE. M. (2021). Inflammation in glaucoma: from the back to the front of the eye and beyond. Prog. Retin. Eye Res.83:100916. 10.1016/j.preteyeres.2020.100916
10
BerdahlJ. P.AllinghamR. R.JohnsonD. H. (2008a). Cerebrospinal fluid pressure is decreased in primary open-angle glaucoma. Ophthalmology115, 763–768. 10.1016/j.ophtha.2008.01.013
11
BerdahlJ. P.FautschM. P.StinnettS. S.AllinghamR. R. (2008b). Intracranial pressure in primary open angle glaucoma, normal tension glaucoma and ocular hypertension: a case-control study. Invest. Ophthalmol. Vis. Sci.49, 5412–5418. 10.1167/iovs.08-2228
12
BiscettiL.LupidiM.LuchettiE.EusebiP.GujarR.VergaroA.et al. (2021). Novel noninvasive biomarkers of prodromal Alzheimer disease: The role of optical coherence tomography and optical coherence tomography-angiography. Eur. J. Neurol.28, 2185–2191. 10.1111/ene.14871
13
BlanksJ. C.SchmidtS. Y.TorigoeY.PorrelloK. V.HintonD. R.BlanksR. H. (1996a). Retinal pathology in Alzheimer’s disease. II. Regional neuron loss and glial changes in GCL. Neurobiol. Aging.17, 385–395. 10.1016/0197-4580(96)00009-7
14
BlanksJ. C.TorigoeY.HintonD. R.BlanksR. H. (1996b). Retinal pathology in Alzheimer’s disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol. Aging17, 377–384. 10.1016/0197-4580(96)00010-3
15
BojikianK. D.ChenP. P.WenJ. C. (2019). Optical coherence tomography angiography in glaucoma. Curr. Opin. Ophthalmol.30, 110–116. 10.1097/ICU.0000000000000554
16
Cerquera-JaramilloM. A.Nava-MesaM. O.González-ReyesR. E.Tellez-ContiC.de-la-TorreA. (2018). Visual features in Alzheimer’s disease: from basic mechanisms to clinical overview. Neural Plast.2018:2941783. 10.1155/2018/2941783
17
ChauhanB. C.MalikR.ShubaL. M.RafuseP. E.NicolelaM. T.ArtesP. H. (2014). Rates of glaucomatous visual field change in a large clinical population. Invest. Ophthalmol. Vis. Sci.55, 4135–4143. 10.1167/iovs.14-14643
18
ChongR. S.MartinK. R. (2015). Glial cell interactions and glaucoma. Curr. Opin. Ophthalmol.26, 73–77. 10.1097/ICU.0000000000000125
19
ChrysostomouV.RezaniaF.TrounceI. A.CrowstonJ. G. (2013). Oxidative stress and mitochondrial dysfunction in glaucoma. Curr. Opin. Pharmacol.13, 12–15. 10.1016/j.coph.2012.09.008
20
Collaborative Normal-Tension Glaucoma Study Group. (1998). The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol.126, 498–505. 10.1016/s0002-9394(98)00272-4
21
ColligrisP.Perez de LaraM. J.ColligrisB.PintorJ. (2018). Ocular manifestations of Alzheimer’s and other neurodegenerative diseases: the prospect of the eye as a tool for the early diagnosis of Alzheimer’s disease. J. Ophthalmol.2018:8538573. 10.1155/2018/8538573
22
CoppolaG.Di RenzoA.ZiccardiL.MartelliF.FaddaA.ManniG.et al. (2015). Optical coherence tomography in Alzheimer’s disease: a meta-analysis. PLoS One10:e0134750. 10.1371/journal.pone.0134750
23
CuercaN. (2019). The retina as a biomarker of Parkinson disease. Invest. Ophthalmol. Vis. Sci60:8.
24
CumurcuT.SahinS.AydinE. (2006). Serum homocysteine, vitamin B 12 and folic acid levels in different types of glaucoma. BMC Ophthalmol.6:6. 10.1186/1471-2415-6-6
25
Diniz-FilhoA.Delano-WoodL.DagaF. B.CronembergerS.MedeirosF. A. (2017). Association between neurocognitive decline and visual field variability in glaucoma. JAMA Ophthalmol.135, 734–739. 10.1001/jamaophthalmol.2017.1279
26
DoozandehA.YazdaniS. (2016). Neuroprotection in Glaucoma. J. Ophthalmic Vis. Res.11, 209–220. 10.4103/2008-322X.183923
27
DreyerE. B.ZurakowskiD.SchumerR. A.PodosS. M.LiptonS. A. (1996). Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol.114, 299–305. 10.1001/archopht.1996.01100130295012
28
El-RafeiA.EngelhornT.WärntgesS.DörflerA.HorneggerJ.MichelsonG. (2013). Glaucoma classification based on visual pathway analysis using diffusion tensor imaging. Magn. Reson. Imaging31, 1081–1091. 10.1016/j.mri.2013.01.001
29
European Glaucoma Prevention Study (EGPS) GroupMigliorS.PfeifferN.TorriV.ZeyenT.Cunha-VazJ.et al. (2007). Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology114, 3–9. 10.1016/j.ophtha.2006.05.075
30
FangJ. H.WangX. H.XuZ. R.JiangF. G. (2010). Neuroprotective effects of bis (7)-tacrine against glutamate-induced retinal ganglion cells damage. BMC Neurosci.11:31. 10.1186/1471-2202-11-31
31
FerreiraS.PereiraA. C.QuenderaB.ReisA.SilvaE. D.Castelo-BrancoM. (2016). Primary visual cortical remapping in patients with inherited peripheral retinal degeneration. Neuroimage Clin.13, 428–438. 10.1016/j.nicl.2016.12.013
32
FlammerJ. (1994). The vascular concept of glaucoma. Surv. Ophthalmol.38, S3–S6. 10.1016/0039-6257(94)90041-8
33
FlammerJ.OrgülS.CostaV. P.OrzalesiN.KrieglsteinG. K.SerraL. M.et al. (2002). The impact of ocular blood flow in glaucoma. Prog. Retin Eye Res.21, 359–393. 10.1016/s1350-9462(02)00008-3
34
FrezzottiP.GiorgioA.MotoleseI.De LeucioA.IesterM.MotoleseE.et al. (2014). Structural and functional brain changes beyond visual system in patients with advanced glaucoma. PLoS One9:e105931. 10.1371/journal.pone.0105931
35
FrezzottiP.GiorgioA.TotoF.De LeucioA.De StefanoN. (2016). Early changes of brain connectivity in primary open angle glaucoma. Hum. Brain Mapp.37, 4581–4596. 10.1002/hbm.23330
36
GaraciF. G.BolacchiF.CerulliA.MelisM.SpanòA.CedroneC.et al. (2009). Optic nerve and optic radiation neurodegeneration in patients with glaucoma: in vivo analysis with 3-T diffusion-tensor MR imaging. Radiology252, 496–501. 10.1148/radiol.2522081240
37
GarbuttS.MatlinA.HellmuthJ.SchenkA. K.JohnsonJ. K.RosenH.et al. (2008). Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer’s disease. Brain131, 1268–1281. 10.1093/brain/awn047
38
GherghelD.GriffithsH. R.HiltonE. J.CunliffeI. A.HoskingS. L. (2005). Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci.46, 877–883. 10.1167/iovs.04-0777
39
GilmoreG. C.GrothK. E.ThomasC. W. (2006). Stimulus contrast and word reading speed in Alzheimer’s disease. Exp. Aging Res.31, 15–33. 10.1080/03610730590882828
40
GiorgioA.ZhangJ.CostantinoF.De StefanoN.FrezzottiP. (2018). Diffuse brain damage in normal tension glaucoma. Hum. Brain Mapp.39, 532–541. 10.1002/hbm.23862
41
GiorgioA.ZhangJ.CostantinoF.De StefanoN.FrezzottiP. (2020). Altered large-scale brain functional connectivity in ocular hypertension. Front. Neurosci.14:146. 10.3389/fnins.2020.00146
42
GlassJ. M. (2007). Visual function and cognitive aging: differential role of contrast sensitivity in verbal versus spatial tasks. Psychol. Aging22, 233–238. 10.1037/0882-7974.22.2.233
43
GordonM. O.BeiserJ. A.BrandtJ. D.HeuerD. K.HigginbothamE. J.JohnsonC. A.et al. (2002). The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch. Ophthalmol.120, 714–720. 10.1001/archopht.120.6.714
44
GrieshaberM. C.FlammerJ. (2005). Blood flow in glaucoma. Curr. Opin. Ophthalmol.16, 79–83. 10.1097/01.icu.0000156134.38495.0b
45
GrieshaberM. C.FlammerJ. (2007). Does the blood-brain barrier play a role in Glaucoma?Surv. Ophthalmol.52, S115–S121. 10.1016/j.survophthal.2007.08.005
46
GrusF. H.JoachimS. C.BrunsK.LacknerK. J.PfeifferN.WaxM. B. (2006). Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States. Invest. Ophthalmol. Vis. Sci.47, 968–976. 10.1167/iovs.05-0685
47
GuoL.NormandoE. M.ShahP. A.De GroefL.CordeiroM. F. (2018). Oculo-visual abnormalities in Parkinson’s disease: possible value as biomarkers. Mov. Disord.33, 1390–1406. 10.1002/mds.27454
48
GuoL.SaltT. E.MaassA.LuongV.MossS. E.FitzkeF. W.et al. (2006). Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. Invest. Ophthalmol. Vis. Sci.47, 626–633. 10.1167/iovs.05-0754
49
HarrabiH.KergoatM. J.RousseauJ.BoisjolyH.SchmaltzH.MoghadaszadehS.et al. (2015). Age-related eye disease and cognitive function. Invest. Ophthalmol. Vis. Sci.56, 1217–1221. 10.1167/iovs.14-15370
50
HarrisA.ZarfatiD.ZalishM.BillerJ.SheetsC. W.RechtmanE.et al. (2003). Reduced cerebrovascular blood flow velocities and vasoreactivity in open-angle glaucoma. Am. J. Ophthalmol.135, 144–147. 10.1016/s0002-9394(02)01927-x
51
HayrehS. S. (1985). Inter-individual variation in blood supply of the optic nerve head. Its importance in various ischemic disorders of the optic nerve head and glaucoma, low-tension glaucoma and allied disorders. Doc. Ophthalmol.59, 217–246. 10.1007/BF00159262
52
HeijlA.LeskeM. C.BengtssonB.HymanL.BengtssonB.HusseinM.et al. (2002). Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch. Ophthalmol.120, 1268–1279. 10.1001/archopht.120.10.1268
53
HeringaS. M.BouvyW. H.van den BergE.MollA. C.KappelleL. J.BiesselsG. J. (2013). Associations between retinal microvascular changes and dementia, cognitive functioning and brain imaging abnormalities: a systematic review. J. Cereb. Blood Flow Metab.33, 983–995. 10.1038/jcbfm.2013.58
54
HernowoA. T.PrinsD.BaselerH. A.PlankT.GouwsA. D.HooymansJ. M.et al. (2014). Morphometric analyses of the visual pathways in macular degeneration. Cortex56, 99–110. 10.1016/j.cortex.2013.01.003
55
HintonD. R.SadunA. A.BlanksJ. C.MillerC. A. (1986). Optic-nerve degeneration in Alzheimer’s disease. N. Engl. J. Med.315, 485–487. 10.1056/NEJM198608213150804
56
HofmanP.HoyngP.vanderWerfF.VrensenG. F.SchlingemannR. O. (2001). Lack of blood-brain barrier properties in microvessels of the prelaminar optic nerve head. Invest. Ophthalmol. Vis. Sci.42, 895–901.
57
HonjoM.NumagaJ.HaraT.AsaokaR. (2017). The association between structure-function relationships and cognitive impairment in elderly glaucoma patients. Sci. Rep.7:7095. 10.1038/s41598-017-07714-7
58
IseriP. K.AltinaşO.TokayT.YükselN. (2006). Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J. Neuroophthalmol.26, 18–24. 10.1097/01.wno.0000204645.56873.26
59
JammalA. A.ThompsonA. C.MariottoniE. B.UrataC. N.EstrelaT.BerchuckS. I.et al. (2021). Rates of glaucomatous structural and functional change from a large clinical population: the duke glaucoma registry study. Am. J. Ophthalmol.222, 238–247. 10.1016/j.ajo.2020.05.019
60
JessenN. A.MunkA. S.LundgaardI.NedergaardM. (2015). The glymphatic system: a beginner’s guide. Neurochem. Res.40, 2583–2599. 10.1007/s11064-015-1581-6
61
JiangS.KametaniM.ChenD. F. (2020). Adaptive immunity: new aspects of pathogenesis underlying neurodegeneration in glaucoma and optic neuropathy. Front. Immunol.11:65. 10.3389/fimmu.2020.00065
62
JiangM. M.ZhouQ.LiuX. Y.ShiC. Z.ChenJ.HuangX. H. (2017). Structural and functional brain changes in early- and mid-stage primary open-angle glaucoma using voxel-based morphometry and functional magnetic resonance imaging. Medicine (Baltimore)96:e6139. 10.1097/MD.0000000000006139
63
JindalV. (2015). Interconnection between brain and retinal neurodegenerations. Mol. Neurobiol.51, 885–892. 10.1007/s12035-014-8733-6
64
JonasJ. B. (2011). Role of cerebrospinal fluid pressure in the pathogenesis of glaucoma. Acta Ophthalmol.89, 505–514. 10.1111/j.1755-3768.2010.01915.x
65
Jones-OdehE.HammondC. J. (2015). How strong is the relationship between glaucoma, the retinal nerve fibre layer and neurodegenerative diseases such as Alzheimer’s disease and multiple sclerosis?Eye (Lond)29, 1270–1284. 10.1038/eye.2015.158
66
JongsiriyanyongS.LimpawattanaP. (2018). Mild cognitive impairment in clinical practice: a review article. Am. J. Alzheimers Dis. Other Demen.33, 500–507. 10.1177/1533317518791401
67
JuW. K.KimK. Y.AngertM.Duong-PolkK. X.LindseyJ. D.EllismanM. H.et al. (2009). Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. Invest. Ophthalmol. Vis. Sci.50, 707–716. 10.1167/iovs.08-2499
68
JuW. K.LiuQ.KimK. Y.CrowstonJ. G.LindseyJ. D.AgarwalN.et al. (2007). Elevated hydrostatic pressure triggers mitochondrial fission and decreases cellular ATP in differentiated RGC-5 cells. Invest. Ophthalmol. Vis. Sci.48, 2145–2151. 10.1167/iovs.06-0573
69
KalapesiF. B.CoroneoM. T.HillM. A. (2005). Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br. J. Ophthalmol.89, 758–763. 10.1136/bjo.2004.053025
70
KasiA.FaiqM. A.ChanK. C. (2019). in vivo imaging of structural, metabolic and functional brain changes in glaucoma. Neural Regen. Res.14, 446–449. 10.4103/1673-5374.243712
71
KavcicV.VaughnW.DuffyC. J. (2011). Distinct visual motion processing impairments in aging and Alzheimer’s disease. Vis. Res.51, 386–395. 10.1016/j.visres.2010.12.004
72
KimK. E.ParkK. H. (2016). Update on the prevalence, etiology, diagnosis and monitoring of normal-tension glaucoma. Asia Pac. J. Ophthalmol. (Phila.)5, 23–31. 10.1097/APO.0000000000000177
73
KirwanJ. F.HustlerA.BobatH.TomsL.CrabbD. P.McNaughtA. I. (2014). Portsmouth visual field database: an audit of glaucoma progression. Eye (Lond)28, 974–979. 10.1038/eye.2013.294
74
KoronyoY.SalumbidesB. C.BlackK. L.Koronyo-HamaouiM. (2012). Alzheimer’s disease in the retina: imaging retinal Aβ plaques for early diagnosis and therapy assessment. Neurodegener. Dis.10, 285–293. 10.1159/000335154
75
KumarD. K.ChoiS. H.WashicoskyK. J.EimerW. A.TuckerS.GhofraniJ.et al. (2016). Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci. Transl. Med.8:340ra72. 10.1126/scitranslmed.aaf1059
76
KumarS.MalikM. A.GoswamiS.SihotaR.KaurJ. (2016). Candidate genes involved in the susceptibility of primary open angle glaucoma. Gene577, 119–131. 10.1016/j.gene.2015.11.032
77
KumarS.MalikM. A.KS.SihotaR.KaurJ. (2017). Genetic variants associated with primary open angle glaucoma in Indian population. Genomics109, 27–35. 10.1016/j.ygeno.2016.11.003
78
LakshminarayananV.LagraveJ.KeanM. L.DickM.ShankleR. (1996). Vision in dementia: contrast effects. Neurol. Res.18, 9–15. 10.1080/01616412.1996.11740369
79
LangeneggerS. J.FunkJ.Töteberg-HarmsM. (2011). Reproducibility of retinal nerve fiber layer thickness measurements using the eye tracker and the retest function of Spectralis SD-OCT in glaucomatous and healthy control eyes. Invest. Ophthalmol. Vis. Sci.52, 3338–3344. 10.1167/iovs.10-6611
80
LeeS. H.HanJ. W.LeeE. J.KimT. W.KimH.KimK. W. (2020). Cognitive impairment and lamina cribrosa thickness in primary open-angle glaucoma. Transl. Vis. Sci. Technol.9:17. 10.1167/tvst.9.7.17
81
LeeE. J.LeeK. M.LeeS. H.KimT. W. (2016). OCT Angiography of the peripapillary retina in primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci.57, 6265–6270. 10.1167/iovs.16-20287
82
LeeY. T.PaiM. C. (2012). Recognition of personality familiar scenes in patients with very mild Alzheimer’s disease: effects of spatial frequency and luminance. J. Alzheimers Dis.29, 441–448. 10.3233/JAD-2011-111601
83
LeskeM. C.WuS. Y.HymanL.NemesureB.HennisA.SchachatA. P.et al. (2004). Four-year incidence of visual impairment: barbados incidence study of eye diseases. Ophthalmology111, 118–124. 10.1016/j.ophtha.2003.04.002
84
LeštákJ.TinteraJ.KarelI.SvatáZ.RozsívalP. (2013). Functional magnetic resonance imaging in patients with the wet form of age-related macular degeneration. Neuroophthalmology37, 192–197. 10.3109/01658107.2013.819581
85
LeungC. K.CheungC. Y.WeinrebR. N.QiuK.LiuS.LiH.et al. (2010). Evaluation of retinal nerve fiber layer progression in glaucoma: a study on optical coherence tomography guided progression analysis. Invest. Ophthalmol. Vis. Sci.51, 217–222. 10.1167/iovs.09-3468
86
LiC.CaiP.ShiL.LinY.ZhangJ.LiuS.et al. (2012). Voxel-based morphometry of the visual-related cortex in primary open angle glaucoma. Curr. Eye Res.37, 794–802. 10.3109/02713683.2012.683506
87
LiF.LinF.GaoK.ChengW.SongY.LiuY.et al. (2021). Association of foveal avascular zone area withstructural and functional progression in glaucoma patients. Br. J. Ophthalmol. [Online ahead of print]. 10.1136/bjophthalmol-2020-318065
88
LiT.QuX.ChenW.WangQ.WangH.WangY.et al. (2020). Altered information flow and microstructure abnormalities of visual cortex in normal-tension glaucoma: evidence from resting-state fMRI and DKI. Brain Res.1741:146874. 10.1016/j.brainres.2020.146874
89
LimJ. K.LiQ. X.HeZ.VingrysA. J.WongV. H.CurrierN.et al. (2016). The eye as a biomarker for Alzheimer’s disease. Front. Neurosci.10:536. 10.3389/fnins.2016.00536
90
LiptonS. A. (2003). Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv. Ophthalmol.48, S38–S46. 10.1016/s0039-6257(03)00008-0
91
LiuD.ZhangL.LiZ.ZhangX.WuY.YangH.et al. (2015). Thinner changes of the retinal nerve fiber layer in patients with mild cognitive impairment and Alzheimer’s disease. BMC Neurol.15:14. 10.1186/s12883-015-0268-6
92
López-RiquelmeN.VillalbaC.TormoC.BelmonteA.FernandezC.TorralbaG.et al. (2015). Endothelin-1 levels and biomarkers of oxidative stress in glaucoma patients. Int. Ophthalmol.35, 527–532. 10.1007/s10792-014-9979-8
93
MallickJ.DeviL.MalikP. K.MallickJ. (2016). Update on normal tension glaucoma. J. Ophthalmic Vis. Res.11, 204–208. 10.4103/2008-322X.183914
94
MauranoS. T. P.da SilvaD. J.ÁvilaM. P.MagachoL. (2018). Cognitive evaluation of patients with glaucoma and its comparison with individuals with Alzheimer’s disease. Int. Ophthalmol.38, 1839–1844. 10.1007/s10792-017-0658-4
95
McCoskeyM.AddisV.GoodyearK.SankarP. S.YingG. S.YuY.et al. (2018). Association between primary open-angle glaucoma and cognitive impairment as measured by the montreal cognitive assessment. Neurodegener. Dis.18, 315–322. 10.1159/000496233
96
McKendrickA. M.SampsonG. P.WallandM. J.BadcockD. R. (2007). Contrast sensitivity changes due to glaucoma and normal aging: low-spatial-frequency losses in both magnocellular and parvocellular pathways. Invest. Ophthalmol. Vis. Sci.48, 2115–2122. 10.1167/iovs.06-1208
97
McKinnonS. J. (2012). The cell and molecular biology of glaucoma: common neurodegenerative pathways and relevance to glaucoma. Invest. Ophthalmol. Vis. Sci.53, 2485–2487. 10.1167/iovs.12-9483j
98
McKinnonS. J.LehmanD. M.Kerrigan-BaumrindL. A.MergesC. A.PeaseM. E.KerriganD. F.et al. (2002). Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest. Ophthalmol. Vis. Sci.43, 1077–1087.
99
MooreD.HarrisA.WudunnD.KheradiyaN.SieskyB. (2008). Dysfunctional regulation of ocular blood flow: a risk factor for glaucoma?Clin. Ophthalmol.2, 849–861. 10.2147/opth.s2774
100
MorganW. H.ChauhanB. C.YuD. Y.CringleS. J.AlderV. A.HouseP. H. (2002). Optic disc movement with variations in intraocular and cerebrospinal fluid pressure. Invest. Ophthalmol. Vis. Sci.43, 3236–3242.
101
MorganW. H.YuD. Y.AlderV. A.CringleS. J.CooperR. L.HouseP. H.et al. (1998). The correlation between cerebrospinal fluid pressure and retrolaminar tissue pressure. Invest. Ophthalmol. Vis. Sci.39, 1419–1428.
102
MorganW. H.YuD. Y.CooperR. L.AlderV. A.CringleS. J.ConstableI. J. (1995). The influence of cerebrospinal fluid pressure on the lamina cribrosa tissue pressure gradient. Invest. Ophthalmol. Vis. Sci.36, 1163–1172.
103
MozaffariehM.FlammerJ. (2013). New insights in the pathogenesis and treatment of normal tension glaucoma. Curr. Opin. Pharmacol.13, 43–49. 10.1016/j.coph.2012.10.001
104
MullanyS.XiaoL.QassimA.MarshallH.GharahkhaniP.MacGregorS.et al. (2021). Normal-tension glaucoma is associated with cognitive impairment. Br. J. Ophthalmol. [Online ahead of print]. 10.1136/bjophthalmol-2020-317461
105
MunemasaY.KitaokaY. (2013). Molecular mechanisms of retinal ganglion cell degeneration in glaucoma and future prospects for cell body and axonal protection. Front. Cell. Neurosci.6:60. 10.3389/fncel.2012.00060
106
NaamanE.Ya’ariS.ItzkovichC.SafuriS.MacsiF.KellermanL.et al. (2020). The retinal toxicity profile towards assemblies of Amyloid-β indicate the predominant pathophysiological activity of oligomeric species. Sci. Rep.10:20954. 10.1038/s41598-020-77712-9
107
NingA.CuiJ.ToE.AsheK. H.MatsubaraJ. (2008). Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest. Ophthalmol. Vis. Sci.49, 5136–5143. 10.1167/iovs.08-1849
108
NuzziR.DallortoL.RolleT. (2018). Changes of visual pathway and brain connectivity in glaucoma: a systematic review. Front. Neurosci.12:363. 10.3389/fnins.2018.00363
109
NuzziR.DallortoL.VitaleA. (2020). Cerebral modifications and visual pathway reorganization in maculopathy: a systematic review. Front. Neurosci.14:755. 10.3389/fnins.2020.00755
110
OlivoG.MelilloP.CocozzaS.D’AlterioF. M.PrinsterA.TestaF.et al. (2015). Cerebral involvement in Stargardt’s disease: A VBM and TBSS study. Invest. Ophthalmol. Vis. Sci.56, 7388–7397. 10.1167/iovs.15-16899
111
OmodakaK.MurataT.SatoS.TakahashiM.TatewakiY.NagasakaT.et al. (2014). Correlation of magnetic resonance imaging optic nerve parameters to optical coherence tomography and the visual field in glaucoma. Clin. Exp. Ophthalmol.42, 360–368. 10.1111/ceo.12237
112
OsborneN. N.MelenaJ.ChidlowG.WoodJ. P. (2001). A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br. J. Ophthalmol.85, 1252–1259. 10.1136/bjo.85.10.1252
113
ParkB. C.TibudanM.SamaraweeraM.ShenX.YueB. Y. (2007). Interaction between two glaucoma genes, optineurin and myocilin. Genes Cells12, 969–979. 10.1111/j.1365-2443.2007.01102.x
114
PascoliniD.MariottiS. P. (2012). Global estimates of visual impairment: 2010. Br. J. Ophthalmol.96, 614–618. 10.1136/bjophthalmol-2011-300539
115
PetersenR. C. (2011). Clinical practice. Mild cognitive impairment. N. Engl. J. Med.364, 2227–2234. 10.1056/NEJMcp0910237
116
PrinsD.HanekampS.CornelissenF. W. (2016). Structural brain MRI studies in eye diseases: are they clinically relevant? A review of current findings. Acta Ophthalmol.94, 113–121. 10.1111/aos.12825
117
QuarantaL.BettelliS.UvaM. G.SemeraroF.TuranoR.GandolfoE. (2003). Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology110, 359–362. 10.1016/S0161-6420(02)01745-1
118
QuarantaL.BruttiniC.MichelettiE.KonstasA. G. P.MichelessiM.OddoneF.et al. (2021). Glaucoma and neuroinflammation: an overview. Surv. Ophthalmol.66, 693–713. 10.1016/j.survophthal.2021.02.003
119
RamanP.Khy ChingY.SivagurunathanP. D.RamliN.Mohd KhalidK. H. (2019). The association between visual field reliability indices and cognitive impairment in glaucoma patients. J. Glaucoma28, 685–690. 10.1097/IJG.0000000000001269
120
RaoV. R.KrishnamoorthyR. R.YorioT. (2007). Endothelin-1, endothelin A and B receptor expression and their pharmacological properties in GFAP negative human lamina cribrosa cells. Exp. Eye Res.84, 1115–1124. 10.1016/j.exer.2007.02.010
121
RaoV. R.KrishnamoorthyR. R.YorioT. (2008). Endothelin-1 mediated regulation of extracellular matrix collagens in cells of human lamina cribrosa. Exp. Eye Res.86, 886–894. 10.1016/j.exer.2008.03.003
122
RegoA. C.OliveiraC. R. (2003). Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem. Res.28, 1563–1574. 10.1023/a:1025682611389
123
RenR.JonasJ. B.TianG.ZhenY.MaK.LiS.et al. (2010). Cerebrospinal fluid pressure in glaucoma: a prospective study. Ophthalmology117, 259–266. 10.1016/j.ophtha.2009.06.058
124
RenR.WangN.ZhangX.CuiT.JonasJ. B. (2011). Trans-lamina cribrosa pressure difference correlated with neuroretinal rim area in glaucoma. Graefes Arch. Clin. Exp. Ophthalmol.249, 1057–1063. 10.1007/s00417-011-1657-1
125
ReznicekL.SeidenstickerF.MannT.HübertI.BuergerA.HaritoglouC.et al. (2013). Correlation between peripapillary retinal nerve fiber layer thickness and fundus autofluorescence in primary open-angle glaucoma. Clin. Ophthalmol.7, 1883–1888. 10.2147/OPTH.S49112
126
RisacherS. L.WudunnD.PepinS. M.MaGeeT. R.McDonaldB. C.FlashmanL. A.et al. (2013). Visual contrast sensitivity in Alzheimer’s disease, mild cognitive impairment and older adults with cognitive complaints. Neurobiol. Aging34, 1133–1144. 10.1016/j.neurobiolaging.2012.08.007
127
Rita MachadoA.Carvalho PereiraA.FerreiraF.FerreiraS.QuenderaB.SilvaE.et al. (2017). Structure-function correlations in Retinitis Pigmentosa patients with partially preserved vision: a voxel-based morphometry study. Sci. Rep.7:11411. 10.1038/s41598-017-11317-7
128
RizzoM.AndersonS. W.DawsonJ.NawrotM. (2000). Vision and cognition in Alzheimer’s disease. Neuropsychologia38, 1157–1169. 10.1038/s41598-017-11317-7
129
RomanoC.BarrettD. A.LiZ.PestronkA.WaxM. B. (1995). Anti-rhodopsin antibodies in sera from patients with normal-pressure glaucoma. Invest. Ophthalmol. Vis. Sci.36, 1968–1975.
130
RomanoC.LiZ.ArendtA.HargraveP. A.WaxM. B. (1999). Epitope mapping of anti-rhodopsin antibodies from patients with normal pressure glaucoma. Invest. Ophthalmol. Vis. Sci.40, 1275–1280.
131
RosengarthK.KeckI.Brandl-RühleS.FroloJ.HufendiekK.GreenleeM. W.et al. (2013). Functional and structural brain modifications induced by oculomotor training in patients with age-related macular degeneration. Front. Psychol.4:428. 10.3389/fpsyg.2013.00428
132
SaltT. E.CordeiroM. F. (2006). Glutamate excitotoxicity in glaucoma: throwing the baby out with the bathwater?Eye (Lond)20, 730–731. 10.1038/sj.eye.6701967
133
Schmitz-ValckenbergS.HolzF. G.BirdA. C.SpaideR. F. (2008). Fundus autofluorescence imaging: review and perspectives. Retina28, 385–409. 10.1097/IAE.0b013e318164a907
134
ScintoL. F. M. (2007). ApoE allelic variability influences pupil response to cholinergic challenge and cognitive impairment. Genes Brain Behav.6, 209–215. 10.1111/j.1601-183X.2006.00247.x
135
SeitzR.OhlmannA.TammE. R. (2013). The role of Müller glia and microglia in glaucoma. Cell Tissue Res.353, 339–345. 10.1007/s00441-013-1666-y
136
SekiM.TanakaT.SakaiY.FukuchiT.AbeH.NawaH.et al. (2005). Müller cells as a source of brain-derived neurotrophic factor in the retina: noradrenaline upregulates brain-derived neurotrophic factor levels in cultured rat Müller cells. Neurochem. Res.30, 1163–1170. 10.1007/s11064-005-7936-7
137
SiaudvytyteL.JanulevicieneI.DaveckaiteA.RagauskasA.BartusisL.KucinovieneJ.et al. (2015). Literature review and meta-analysis of translaminar pressure difference in open-angle glaucoma. Eye (Lond)29, 1242–1250. 10.1038/eye.2015.127
138
SiaudvytyteL.JanulevicieneI.RagauskasA.BartusisL.MeiliunieneI.SieskyB.et al. (2014). The difference in translaminar pressure gradient and neuroretinal rim area in glaucoma and healthy subjects. J. Ophthalmol.2014:937360. 10.1155/2014/937360
139
SivakJ. M. (2013). The aging eye: common degenerative mechanisms between the Alzheimer’s brain and retinal disease. Invest. Ophthalmol. Vis. Sci.54, 871–880. 10.1167/iovs.12-10827
140
SpaideR. F.FujimotoJ. G.WaheedN. K.SaddaS. R.StaurenghiG. (2018). Optical coherence tomography angiography. Prog. Retin Eye Res.64, 1–55.
141
StasiK.NagelD.YangX.WangR. F.RenL.PodosS. M.et al. (2006). Complement component 1Q (C1Q) upregulation in retina of murine, primate and human glaucomatous eyes. Invest. Ophthalmol. Vis. Sci.47, 1024–1029. 10.1167/iovs.05-0830
142
SuC. W.LinC. C.KaoC. H.ChenH. Y. (2016). Association between glaucoma and the risk of dementia. Medicine (Baltimore)95:e2833. 10.1097/MD.0000000000002833
143
SungM. S.ChoiS. M.KimJ.HaJ. Y.KimB. C.HeoH.et al. (2019). Inner retinal thinning as a biomarker for cognitive impairment in de novo Parkinson’s disease. Sci. Rep.9:11832. 10.1038/s41598-019-48388-7
144
SzatkowskiM.AttwellD. (1994). Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci.17, 359–365. 10.1016/0166-2236(94)90040-x
145
TamuraH.KawakamiH.KanamotoT.KatoT.YokoyamaT.SasakiK.et al. (2006). High frequency of open-angle glaucoma in Japanese patients with Alzheimer’s disease. J. Neurol. Sci.246, 79–83. 10.1016/j.jns.2006.02.009
146
TezelG. (2006). Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog. Retin Eye Res.25, 490–513. 10.1016/j.preteyeres.2006.07.003
147
TezelG. (2008). TNF-alpha signaling in glaucomatous neurodegeneration. Prog. Brain Res.173, 409–421. 10.1016/S0079-6123(08)01128-X
148
TezelG. (2021). Multifactorial pathogenic processes of retinal ganglion cell degeneration in glaucoma towards multi-target strategies for broader treatment effects. Cells10:1372. 10.3390/cells10061372
149
TezelG.EdwardD. P.WaxM. B. (1999). Serum autoantibodies to optic nerve head glycosaminoglycans in patients with glaucoma. Arch. Ophthalmol.117, 917–924. 10.1001/archopht.117.7.917
150
TezelG.SeigelG. M.WaxM. B. (1998). Autoantibodies to small heat shock proteins in glaucoma. Invest. Ophthalmol. Vis. Sci.39, 2277–2287.
151
TezelG.WaxM. B. (2000). Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J. Neurosci.20, 8693–8700. 10.1523/JNEUROSCI.20-23-08693.2000
152
TezelG.WaxM. B. (2004). The immune system and glaucoma. Curr. Opin. Ophthalmol.15, 80–84. 10.1097/00055735-200404000-00003
153
ThamY. C.LiX.WongT. Y.QuigleyH. A.AungT.ChengC. Y. (2014). Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology121, 2081–2090. 10.1016/j.ophtha.2014.05.013
154
The AGIS Investigators. (2000). The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol.130, 429–440. 10.1016/s0002-9394(00)00538-9
155
ThomasD.DuguidG. (2004). Optical coherence tomography–a review of the principles and contemporary uses in retinal investigation. Eye (Lond)18, 561–570. 10.1038/sj.eye.6700729
156
TongY.WangT.ZhangX.HeY.JiangB. (2021). Optical coherence tomography evaluation of peripapillary and macular structure changes in pre-perimetric glaucoma, early perimetric glaucoma and ocular hypertension: a systematic review and meta-analysis. Front. Med. (Lausanne)8:696004. 10.3389/fmed.2021.696004
157
TrickG. L.TrickL. R.MorrisP.WolfM. (1995). Visual field loss in senile dementia of the Alzheimer’s type. Neurology45, 68–74.
158
TurgutB.KayaM.ArslanS.DemirT.GülerM.KayaM. K. (2010). Levels of circulating homocysteine, vitamin B6, vitamin B12 and folate in different types of open-angle glaucoma. Clin. Interv. Aging5, 133–139. 10.2147/cia.s9918
159
TürkcüF. M.KözO. G.YarangümeliA.OnerV.KuralG. (2013). Plasma homocysteine, folic acid and vitamin B12 levels in patients with pseudoexfoliation syndrome, pseudoexfoliation glaucoma and normotensive glaucoma. Medicina (Kaunas)49, 214–218.
160
van de KreekeJ. A.NguyenH. T.KonijnenbergE.TomassenJ.den BraberA.Ten KateM.et al. (2020). Optical coherence tomography angiography in preclinical Alzheimer’s disease. Br. J. Ophthalmol.104, 157–161. 10.1136/bjophthalmol-2019-314127
161
Van MelkebekeL.Barbosa-BredaJ.HuygensM.StalmansI. (2018). Optical coherence tomography angiography in glaucoma: a review. Ophthalmic Res.60, 139–151. 10.1159/000488495
162
VaradarajV.MunozB.DealJ. A.AnY.AlbertM. S.ResnickS. M.et al. (2021). Association of vision impairment with cognitive decline across multiple domains in older adults. JAMA Netw. Open4:e2117416. 10.1001/jamanetworkopen.2021.17416
163
VarinM.KergoatM. J.BellevilleS.LiG.RousseauJ.Roy-GagnonM. H.et al. (2020). Age-related eye disease and cognitive function: the search for mediators. Ophthalmology127, 660–666. 10.1016/j.ophtha.2019.10.004
164
VidalK. S.SuemotoC. K.MorenoA. B.DuncanB.SchmidtM. I.MaestriM.et al. (2020). Association between cognitive performance and self-reported glaucoma in middle-aged and older adults: a cross-sectional analysis of ELSA-Brasil. Braz. J. Med. Biol. Res.53:e10347. 10.1590/1414-431X202010347
165
ViestenzA.LangenbucherA.LaemmerR.MardinC. Y.NaumannG. O. H. (2006). Parapapillary fundus autofluorescence is an glaucoma indicator. Invest. Ophthalmol. Vis. Sci47:3656.
166
VolkertM. R.CrowleyD. J. (2020). Preventing neurodegeneration by controlling oxidative stress: the role of OXR1. Front. Neurosci.14:611904. 10.3389/fnins.2020.611904
167
VrabecJ. P.LevinL. A. (2007). The neurobiology of cell death in glaucoma. Eye (Lond)21, S11–S14. 10.1038/sj.eye.6702880
168
VuD. M.BrahmajothiM. V.Abou-DoniaM. B.TsengH. (2019). Serum autoantibody biomarkers of neuroinflammation and neurodegeneration in glaucoma. Invest. Ophthalmol. Vis. Sci60:680. 10.1186/s12974-016-0542-6
169
WangJ.LiT.ZhouP.WangN.XianJ.HeH. (2017). Altered functional connectivity within and between the default model network and the visual network in primary open-angle glaucoma: a resting-state fMRI study. Brain Imaging Behav.11, 1154–1163. 10.1007/s11682-016-9597-3
170
WangX.LouN.EberhardtA.YangY.KuskP.XuQ.et al. (2020). An ocular glymphatic clearance system removes β-amyloid from the rodent eye. Sci. Transl. Med.12:eaaw3210. 10.1126/scitranslmed.aaw3210
171
WangL.MaoX. (2021). Role of retinal amyloid-β in neurodegenerative diseases: overlapping mechanisms and emerging clinical applications. Int. J. Mol. Sci.22:2360. 10.3390/ijms22052360
172
WangQ.QuX.ChenW.WangH.HuangC.LiT.et al. (2021). Altered coupling of cerebral blood flow and functional connectivity strength in visual and higher order cognitive cortices in primary open angle glaucoma. J. Cereb. Blood Flow Metab.41, 901–913. 10.1177/0271678X20935274
173
WangX.ZhaoQ.TaoR.LuH.XiaoZ.ZhengL.et al. (2021). Decreased retinal vascular density in Alzheimer’s disease (AD) and mild cognitive impairment (MCI): an optical coherence tomography angiography (OCTA) study. Front. Aging Neurosci.12:572484. 10.3389/fnagi.2020.572484
174
WeiX.ChoK. S.TheeE. F.JagerM. J.ChenD. F. (2019). Neuroinflammation and microglia in glaucoma: time for a paradigm shift. J. Neurosci. Res.97, 70–76. 10.1002/jnr.24256
175
WensorM. D.McCartyC. A.StanislavskyY. L.LivingstonP. M.TaylorH. R. (1998). The prevalence of glaucoma in the melbourne visual impairment project. Ophthalmology105, 733–739. 10.1016/S0161-6420(98)94031-3
176
WilliamsA. L.LackeyJ.WizovS. S.ChiaT. M.GatlaS.MosterM. L.et al. (2013). Evidence for widespread structural brain changes in glaucoma: a preliminary voxel-based MRI study. Invest. Ophthalmol. Vis. Sci.54, 5880–5887. 10.1167/iovs.13-11776
177
WilsonR. S.Mendes De LeonC. F.BarnesL. L.SchneiderJ. A.BieniasJ. L.EvansD. A.et al. (2002). Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA287, 742–748. 10.1001/jama.287.6.742
178
WostynP.De GrootV.Van DamD.AudenaertK.KillerH. E.De DeynP. P. (2016). Age-related macular degeneration, glaucoma and Alzheimer’s disease: amyloidogenic diseases with the same glymphatic background?Cell. Mol. Life Sci.73, 4299–4301. 10.1007/s00018-016-2348-1
179
WostynP.Van DamD.AudenaertK.KillerH. E.De DeynP. P.De GrootV. (2015). A new glaucoma hypothesis: a role of glymphatic system dysfunction. Fluids Barriers CNS12:16. 10.1186/s12987-015-0012-z
180
WuDunnD.TakusagawaH. L.SitA. J.RosdahlJ. A.RadhakrishnanS.HoguetA.et al. (2021). OCT angiography for the diagnosis of glaucoma: a report by the American academy of ophthalmology. Ophthalmology128, 1222–1235. 10.1016/j.ophtha.2020.12.027
181
XuX. H.ZouJ. Y.GengW.WangA. Y. (2019). Association between glaucoma and the risk of Alzheimer’s disease: a systematic review of observational studies. Acta Ophthalmol.97, 665–671. 10.1111/aos.14114
182
YuL.XieB.YinX.LiangM.EvansA. C.WangJ.et al. (2013). Reduced cortical thickness in primary open-angle glaucoma and its relationship to the retinal nerve fiber layer thickness. PLoS One8:e73208. 10.1371/journal.pone.0073208
183
ZhangS.WangB.XieY.ZhuS.ThomasR.QingG.et al. (2015). Retinotopic changes in the gray matter volume and cerebral blood flow in the primary visual cortex of patients with primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci.56, 6171–6178. 10.1167/iovs.15-17286
184
ZhangP.WenW.SunX.HeS. (2016). Selective reduction of fMRI responses to transient achromatic stimuli in the magnocellular layers of the LGN and the superficial layer of the SC of early glaucoma patients. Hum. Brain Mapp.37, 558–569. 10.1002/hbm.23049
185
ZhaoX.SunR.LuoX.WangF.SunX. (2021). The interaction between microglia and macroglia in glaucoma. Front. Neurosci.15:610788. 10.1167/iovs.15-17286
186
ZhouW.MuirE. R.ChalfinS.NagiK. S.DuongT. Q. (2017). MRI study of the posterior visual pathways in primary open angle glaucoma. J. Glaucoma26, 173–181. 10.1097/IJG.0000000000000558
187
ZikouA. K.KitsosG.TzarouchiL. C.AstrakasL.AlexiouG. A.ArgyropoulouM. I. (2012). Voxel-based morphometry and diffusion tensor imaging of the optic pathway in primary open-angle glaucoma: a preliminary study. Am. J. Neuroradiol.33, 128–134. 10.3174/ajnr.A2714
Summary
Keywords
glaucoma, neurodegenerative disease, cognitive impairment, neurodegeneration, neuroinflammation, neuroprotection, OCT, OCTA
Citation
Arrigo A, Aragona E, Saladino A, Arrigo D, Fantaguzzi F, Battaglia Parodi M and Bandello F (2021) Cognitive Dysfunctions in Glaucoma: An Overview of Morpho-Functional Mechanisms and the Impact on Higher-Order Visual Function. Front. Aging Neurosci. 13:747050. doi: 10.3389/fnagi.2021.747050
Received
25 July 2021
Accepted
27 August 2021
Published
06 October 2021
Volume
13 - 2021
Edited by
Gemma Caterina Maria Rossi, Fondazione Ospedale San Matteo (IRCCS), Italy
Reviewed by
Raghu R. Krishnamoorthy, University of North Texas Health Science Center, United States; Yasushi Kitaoka, St. Marianna University School of Medicine, Japan; Huaizhou Wang, Capital Medical University, China
Updates
Copyright
© 2021 Arrigo, Aragona, Saladino, Arrigo, Fantaguzzi, Battaglia Parodi and Bandello.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alessandro Arrigo alessandro.arrigo@hotmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.